An Assessment of the Medical Biotechnology Industry in Singapore PDF Download

Author: Diana Guan Boon Chia
Publisher:
ISBN:
Category :
Languages : en
Pages : 57

View

Book Description

Author: Bryan Bergeron
Publisher: John Wiley & Sons
ISBN: 0471647578
Category : Business & Economics
Languages : en
Pages : 384

View

Book Description
"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.

Author: P Omkar Nadh
Publisher: Taylor & Francis
ISBN: 1000592251
Category : Social Science
Languages : en
Pages : 173

View

Book Description
This book examines the medical biotechnology industry in India through the lens of a critical political economy. It discusses the sharp trajectory of growth in the biotechnology business and the state of investments, subsidies, and patents which propelled the rise of the industry in India. The book uses in-depth interviews and case studies to analyse the roles of various financial actors, state institutions, and academia in the medical biotechnology ecosystem. Focusing on the relationship between India’s neoliberal policies and the swift growth of the industry, the author examines the merits and demerits of the current market-driven biomedical ecosystem exploring the trends in the industry, biomedical start-ups, the use of human resources, and capital accumulation process. The book reiterates and emphasises the need for the democratisation of scientific and medical work and for striking a balance between economic gains and public health priorities. Comprehensive and insightful, this book will be of interest to scholars and researchers of science technology society studies, public health, economics, business studies, medical sociology, public policy, and political science.

Author: Shawn Hsia
Publisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 138

View

Book Description

Author: Emma Armitage
Publisher:
ISBN:
Category : Biotechnology industries
Languages : en
Pages : 188

View

Book Description
In 2000, Singapore's government launched a strategy to establish the biotechnology industry as one of the pillars of its future economic growth. This targeted 'causative' process involved support policies, the creation and strengthening of research bodies, construction of a purpose-built bio-hub, attraction of foreign drug companies, and investment in local start-ups. These organisations, support factors, and the networks between them constitute Singapore's national innovation system as it relates to biotech. Fourteen years on, Singapore's causative approach has resulted in job creation and increased per capita income. It has also seen many of biotechnology's top multinational corporations base a section of their operations within the country. However, the country's innovation system has yet to produce a community of Singapore-started small and medium sized dedicated biotechnology firms, referred to here as SDBFs. Small and medium sized firms are key drivers of innovation in the biotechnology sector and their presence is necessary to create a sustainable cluster. There is considerable interest from academia and industry in understanding and learning from the development of Singapore's local firms under its national innovation system. Hence, the purpose of this thesis is to study how Singapore's national innovation system has affected its biotechnology sector, with particular focus on its effect on SDBFs. This thesis used mixed methods to investigate the research question. The quantitative approach involved the construction of a database of Singapore-started biotechnology firms and their characteristics. The qualitative method utilised semi-structured interviews with 16 professionals in Singapore's biotechnology sector. The findings pointed to several key conclusions. Firstly, participants felt that increases in the availability of commercialisable patents, risk-comfortable venture capitalists, and entrepreneurial individuals are necessary factors to promote the emergence and success of start-up firms. Findings also showed that the majority of SDBFs studied are located outside of purpose-built hubs, which participants suggested might influence their business model. In addition, SDBFs appeared to be moving into the relatively 'lower risk' sub-sector of medical devices. Overall, a critical mass of firms, human capital, and support factors emerged as a state that Singapore must reach for the industry to thrive. This research builds on the body of work concerning the national innovation system framework and Singapore's biotechnology industry. It acts as a snapshot in time of SDBFs and the perspectives of a sample of individuals in the biotechnology industry. The data gathered here outlines the effect Singapore's national innovation system has had on the industry and emphasises the importance of the critical mass concept. This can be used to inform future policies and as an indicator of the characteristics of the SDBF level of the industry.

Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241

View

Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--

Author: William A. Haseltine
Publisher: Brookings Institution Press
ISBN: 0815724160
Category : Business & Economics
Languages : en
Pages : 198

View

Book Description
"Today Singapore ranks sixth in the world in healthcare outcomes well ahead of many developed countries, including the United States. The results are all the more significant as Singapore spends less on healthcare than any other high-income country, both as measured by fraction of the Gross Domestic Product spent on health and by costs per person. Singapore achieves these results at less than one-fourth the cost of healthcare in the United States and about half that of Western European countries. Government leaders, presidents and prime ministers, finance ministers and ministers of health, policymakers in congress and parliament, public health officials responsible for healthcare systems planning, finance and operations, as well as those working on healthcare issues in universities and think-tanks should know how this system works to achieve affordable excellence."--Publisher's website.

Author: Lawton R. Burns
Publisher: Cambridge University Press
ISBN: 9780521838986
Category : Business & Economics
Languages : en
Pages : 400

View

Book Description
The first wide-ranging analysis of business trends in the manufacturing segment of the health care industry.

Author: Albert Sasson
Publisher: United Nations University Press
ISBN: 9280811142
Category : Medical
Languages : en
Pages : 165

View

Book Description
" The findings of this book are a valuable contribution to the state of our knowledge about modern biotechnology, to UNU-IAS efforts to raise awareness among policy makers and stakeholders and to educating the public at large about the greater implications and prospects concerning the advances of this rapidly growing new technology." -- From the Foreword by A. H. Zakri, Director of the United Nations University Institute of Advanced Studies

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309316553
Category : Science
Languages : en
Pages : 158

View

Book Description
The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.